Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply

JAMA Oncol. 2022 Apr 1;8(4):1. doi: 10.1001/jamaoncol.2021.7790.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Squamous Cell* / drug therapy
  • Epithelial Cells
  • Humans
  • Ipilimumab / adverse effects
  • Lung Neoplasms* / drug therapy
  • Nivolumab / adverse effects

Substances

  • Ipilimumab
  • Nivolumab